TRT Gel denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt gel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Testosterone Gel

UnitedHealthcare requires prior authorization (PA) for testosterone replacement therapy products, including topical gels, across most commercial and Medicare Advantage plans. A PA denial — or a claim denial citing "prior authorization required" — means the prescription was dispensed without an approved PA on file, or that a PA was submitted but did not satisfy UHC's clinical criteria. Either situation is fully appealable.

## The Two Tracks: Retroactive vs. Prospective

If the medication was already dispensed (retroactive): You are appealing a claim denial. File an internal appeal within 180 days under ERISA §503. Simultaneously, your prescriber should submit a PA request prospectively so future fills are covered while the appeal is pending.

If the PA was denied prospectively: You are appealing the PA denial directly. UHC must respond within 30 days for standard PA appeals and 72 hours for expedited. After an internal denial, you have approximately four months to request independent external review under ACA §2719 — the IRO's decision is binding on the plan.

## Your Federal Appeal Rights

• Internal appeal: 180 days from denial; 30-day standard / 72-hour expedited response.
• External review (ACA §2719): After final internal denial; binding IRO decision.
• Expedited option: Always request expedited when delay would seriously harm health.

## What to Gather

1. Completed PA request with clinical attachments — UHC's PA form for testosterone, with all clinical fields complete. An incomplete submission is the leading cause of PA denial. 2. Confirmed diagnosis — lab reports with clinician interpretation documenting hypogonadism and symptomatic presentation. 3. Prescriber medical-necessity letter — explains clinical rationale for topical gel, patient-specific factors, and how the patient meets the criteria stated in UHC's PA guidelines. 4. Prior-treatment history — records of any prior testosterone therapy or hormonal treatment, with dates and outcomes. 5. Guideline support — reference to the Endocrine Society or American Urological Association guidance on hypogonadism treatment to anchor the clinical rationale.

## Criteria-Mapping Structure

Download UHC's current prior-authorization criteria for testosterone products (available via UHC's provider portal). Map every listed criterion to the chart:

| PA Criterion | Supporting Document | |---|---| | Confirmed hypogonadism diagnosis | Lab report [date], physician note | | Symptom documentation | Office note [date], listed symptoms | | Prescriber specialty requirement (if any) | Prescriber credentials | | Step-therapy or prior-treatment requirement (if any) | Prior-treatment records |

A peer-to-peer consultation between your prescriber and UHC's medical director resolves many PA denials at the internal-appeal stage — request this explicitly in your appeal letter.